You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 20, 2025

CLINICAL TRIALS PROFILE FOR REVATIO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Revatio

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00359736 ↗ Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis Completed VA Office of Research and Development Phase 2 2006-07-01 Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.
NCT00452218 ↗ Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) Completed Bayer Phase 1 2007-03-01 The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
NCT00452218 ↗ Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) Completed University of Chicago Phase 1 2007-03-01 The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
NCT00507819 ↗ Sildenafil After the Fontan Operation Completed The Mark H. and Blanche M. Harrington Foundation Phase 2 2007-12-01 In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation. The investigators will also evaluate echocardiographic measures of ventricular function and measure quality of life changes using two validated quality of life measures. The hypothesis is that sildenafil will result in increased exercise tolerance in patients who have had the Fontan operation as compared to placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Revatio

Condition Name

Condition Name for Revatio
Intervention Trials
Pulmonary Arterial Hypertension 9
Pulmonary Hypertension 7
Hypertension, Pulmonary 5
Cystic Fibrosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Revatio
Intervention Trials
Hypertension 24
Hypertension, Pulmonary 17
Pulmonary Arterial Hypertension 12
Familial Primary Pulmonary Hypertension 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Revatio

Trials by Country

Trials by Country for Revatio
Location Trials
United States 120
Germany 18
Canada 14
Spain 8
Belgium 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Revatio
Location Trials
North Carolina 10
California 8
New York 7
Texas 6
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Revatio

Clinical Trial Phase

Clinical Trial Phase for Revatio
Clinical Trial Phase Trials
Phase 4 9
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Revatio
Clinical Trial Phase Trials
Completed 41
Terminated 9
Recruiting 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Revatio

Sponsor Name

Sponsor Name for Revatio
Sponsor Trials
Pfizer 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 8
National Heart, Lung, and Blood Institute (NHLBI) 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Revatio
Sponsor Trials
Other 78
Industry 36
NIH 15
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revatio: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction to Revatio

Revatio, developed by Pfizer, is a formulation of sildenafil specifically approved for the treatment of pulmonary arterial hypertension (PAH). PAH is a chronic condition characterized by high blood pressure in the lungs, which can severely impact the heart and lungs, making physical activity more difficult.

Clinical Trials and Efficacy

Overview of Clinical Trials

The clinical development of sildenafil for PAH involved a robust series of trials. A total of 30 clinical trials were conducted, with 24 of these trials being directly relevant to the treatment of PAH. Additionally, 15 more clinical trials were conducted post-approval to further assess the drug's efficacy and safety[1].

Key Clinical Studies

Two pivotal clinical studies, A1481140 and A1481141, were part of Revatio's PAH development program. These studies demonstrated that Revatio significantly improved exercise capacity and delayed clinical worsening in patients with PAH. In adults, the drug increased the distance patients could walk in 6 minutes by 49 meters for those with class II disease and by 45 meters for those with class III disease, compared to placebo[4].

In pediatric patients, a main study involving 235 children aged 1 to 17 years showed that Revatio increased the maximum volume of oxygen used during exercise by 10.2% after 16 weeks, compared to a 0.5% increase with placebo[4].

Dosage and Administration

Revatio is administered orally at a recommended dose of 20 mg three times a day for adults, with the option to titrate up to a maximum of 80 mg three times a day based on symptoms and tolerability. For pediatric patients, the dosage varies by weight: 10 mg three times a day for patients ≤20 kg, 20 mg three times a day for patients 20 kg to 45 kg, and up to 40 mg three times a day for patients >45 kg if necessary[3].

Mechanism of Action

Revatio works by inhibiting the phosphodiesterase type-5 (PDE5) enzyme, which is responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the pulmonary vasculature muscle cells. By blocking PDE5, sildenafil increases cGMP levels, leading to the relaxation and widening of the blood vessels in the lungs, thereby reducing blood pressure and improving symptoms of PAH[1][4].

Market Analysis

Current Market Landscape

As of 2009, the worldwide market for PAH was estimated to be worth $2.653 billion. Actelion Pharmaceuticals’ Tracleer was the leading drug in this market, but its patent expiration in 2015 was expected to shift market share to other drugs, including Revatio. The approval of Revatio's intravenous formulation positioned it favorably against competitors like Remodulin, Flolan, and Ventavis[1].

Market Projections

The approval of the intravenous formulation of Revatio in 2009 and 2010 in the US and EU, respectively, was expected to increase its market share. Given its availability in both oral and intravenous forms, Revatio was well-positioned to capture a significant portion of the PAH market. The drug's unique dosing flexibility and proven efficacy were key factors in its market competitiveness[1].

Competitive Landscape

The PAH market is dynamic, with several drugs competing for market share. However, Revatio's dual formulation and strong clinical trial data make it a significant player. The market is expected to grow as new treatments emerge and existing ones continue to demonstrate efficacy and safety.

Safety and Contraindications

Safety Profile

Revatio has a generally favorable safety profile but comes with several important contraindications and precautions. It must not be taken by patients with non-arteritic anterior ischemic optic neuropathy (NAION), those using nitrates, or those taking certain antifungal and HIV medications. Additionally, it is contraindicated in patients with severe liver disease, severe hypotension, or those who have recently had a stroke or heart attack[3][4].

Common Adverse Effects

Common adverse effects include epistaxis (nosebleeds), particularly in patients with PAH secondary to connective tissue disease or those taking concomitant vitamin K antagonists. Visual loss, though rare, is a potential risk associated with PDE5 inhibitors[3].

Market Trends and Future Outlook

Growing Demand for PAH Treatments

The demand for PAH treatments is expected to increase due to the chronic nature of the disease and the lack of a cure. As the global healthcare landscape evolves, there will be a greater focus on managing and treating PAH effectively.

Competitive Market Dynamics

The PAH market is highly competitive, with several drugs vying for market share. However, Revatio's unique position with both oral and intravenous formulations gives it a competitive edge. The market is expected to see significant growth as new treatments are developed and existing ones continue to demonstrate their efficacy.

Key Takeaways

  • Clinical Efficacy: Revatio has demonstrated significant improvements in exercise capacity and delayed clinical worsening in PAH patients through robust clinical trials.
  • Market Position: The drug's availability in both oral and intravenous forms positions it favorably in the PAH market.
  • Safety Profile: While generally safe, Revatio has important contraindications and precautions that must be considered.
  • Market Growth: The PAH market is expected to grow, driven by the chronic nature of the disease and the need for effective treatments.

FAQs

What is Revatio used for?

Revatio is used for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening in adults and pediatric patients.

How does Revatio work?

Revatio works by inhibiting the PDE5 enzyme, which increases cGMP levels in the pulmonary vasculature, leading to the relaxation and widening of blood vessels in the lungs.

What are the recommended dosages for Revatio?

For adults, the recommended dosage is 20 mg three times a day, with the option to titrate up to 80 mg three times a day. For pediatric patients, dosages vary by weight: 10 mg three times a day for ≤20 kg, 20 mg three times a day for 20 kg to 45 kg, and up to 40 mg three times a day for >45 kg if necessary.

What are the common adverse effects of Revatio?

Common adverse effects include epistaxis (nosebleeds) and visual loss, although the latter is rare.

Can Revatio be used with other medications?

Revatio must not be taken with nitrates, certain antifungal medications, or HIV medications like ritonavir. It also has precautions for use with vitamin K antagonists.

Sources

  1. Clinical Trials Arena: Revatio (Sildenafil) - Treatment for Pulmonary Arterial Hypertension[1].
  2. GlobalData: Heart Failure – Global Drug Forecast and Market Analysis to 2025[2].
  3. FDA: CENTER FOR DRUG EVALUATION AND RESEARCH - Revatio[3].
  4. European Medicines Agency: Revatio - EPAR[4].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.